Literature DB >> 34268675

Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs).

Sanjay Kalra1, Saptarshi Bhattacharya2, Nitin Kapoor3,4.   

Abstract

This communication provides a contemporary classification of glucagon-like peptide 1 receptor agonists (GLP1RAs) based on indication, route, and frequency of administration, which could support a person-centric approach to treatment choice. It includes all recently developed GLP1RAs as well as those in advanced stages of clinical study. Keeping pace with current trends in pharmacology and metabolic medicine, it attempts to bring clarity and simplicity to a complex spread of information.
© 2021. The Author(s).

Entities:  

Keywords:  Danuglipron; Dulaglutide; Exenatide; Exenatide LAR; GLP1RA; IDegLira; IcoSema; Liraglutide; LixiLan; Person-centric care; Semaglutide; Tirzepatide

Year:  2021        PMID： 34268675     DOI： 10.1007/s13300-021-01113-y

Source DB:  PubMed          Journal:  Diabetes Ther        ISSN： 1869-6961            Impact factor:   2.945


  59 in total

Review 1.  A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials.

Authors:  Vanita R Aroda
Journal:  Diabetes Obes Metab       Date:  2018-02       Impact factor: 6.577

2.  Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials.

Authors:  John B Buse; Alan Garber; Julio Rosenstock; Wolfgang E Schmidt; Jason H Brett; Nicoline Videbæk; Jens Holst; Michael Nauck
Journal:  J Clin Endocrinol Metab       Date:  2011-03-30       Impact factor: 5.958

3.  Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment.

Authors:  Mark S Fineman; K F Mace; M Diamant; T Darsow; B B Cirincione; T K Booker Porter; L A Kinninger; M E Trautmann
Journal:  Diabetes Obes Metab       Date:  2012-02-10       Impact factor: 6.577

Review 4.  Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

Review 5.  Exenatide efficacy and safety: a systematic review.

Authors:  S L Norris; N Lee; S Thakurta; B K S Chan
Journal:  Diabet Med       Date:  2009-09       Impact factor: 4.359

6.  Exenatide once weekly: clinical outcomes and patient satisfaction.

Authors:  Biju Jose; Abd A Tahrani; Milan K Piya; Anthony H Barnett
Journal:  Patient Prefer Adherence       Date:  2010-09-07       Impact factor: 2.711

7.  Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes.

Authors:  Anthony H Barnett
Journal:  Core Evid       Date:  2011-09-08

Review 8.  Comparative effectiveness of liraglutide in the treatment of type 2 diabetes.

Authors:  Mauro Rigato; Gian Paolo Fadini
Journal:  Diabetes Metab Syndr Obes       Date:  2014-03-18       Impact factor: 3.168

Review 9.  An overview of GLP-1 agonists and recent cardiovascular outcomes trials.

Authors:  Kelsey H Sheahan; Elizabeth A Wahlberg; Matthew P Gilbert
Journal:  Postgrad Med J       Date:  2019-12-04       Impact factor: 2.401

10.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse
Journal:  N Engl J Med       Date:  2016-06-13       Impact factor: 176.079
View more
  5 in total

Review 1.  GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?

Authors:  Maurício Reis Pedrosa; Denise Reis Franco; Hannah Waisberg Gieremek; Camila Maia Vidal; Fernanda Bronzeri; Alexia de Cassia Rocha; Luis Gabriel de Carvalho Cara; Sofia Lenzi Fogo; Freddy Goldberg Eliaschewitz
Journal:  Curr Atheroscler Rep       Date:  2022-08-31       Impact factor: 5.967

2.  Oral Semaglutide: Dosage in Special Situations.

Authors:  Sanjay Kalra; Nitin Kapoor
Journal:  Diabetes Ther       Date:  2022-05-07       Impact factor: 3.595

Review 3.  A Review of Oral Semaglutide Available Evidence: A New Era of Management of Diabetes with Peptide in a Pill Form.

Authors:  Sanjay Kalra; Sambit Das; Abdul H Zargar
Journal:  Indian J Endocrinol Metab       Date:  2022-06-06

4.  ESI Clinical Practice Guidelines for the Evaluation and Management of Obesity In India.

Authors:  Madhu S V; Kapoor Nitin; Das Sambit; Raizada Nishant; Kalra Sanjay
Journal:  Indian J Endocrinol Metab       Date:  2022-09-16

5.  An Overview of Appetite-Regulatory Peptides in Addiction Processes; From Bench to Bed Side.

Authors:  Olesya T Shevchouk; Maximilian Tufvesson-Alm; Elisabet Jerlhag
Journal:  Front Neurosci       Date:  2021-12-09       Impact factor: 4.677
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.